Page 10«..9101112..20..»

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

By Dr. Matthew Watson

Submitted a premarket approval (PMA) to the FDA for LungFit™ PH to treat persistent pulmonary hypertension of the newborn (PPHN)

See the rest here:
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

To Read More: Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update | dataNovember 12th, 2020
Read All

Retrophin to Present at Upcoming Investor Conferences

By Dr. Matthew Watson

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and December:

Continue reading here:
Retrophin to Present at Upcoming Investor Conferences

To Read More: Retrophin to Present at Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Retrophin to Present at Upcoming Investor Conferences | dataNovember 12th, 2020
Read All

Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences

By Dr. Matthew Watson

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present general company updates at the following investor conferences scheduled in November:

See the original post:
Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences

To Read More: Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences
categoriaGlobal News Feed commentoComments Off on Amarin to Present at the Stifel 2020 Virtual Healthcare and Jefferies Virtual London Healthcare Conferences | dataNovember 12th, 2020
Read All

Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20

By Dr. Matthew Watson

– Event will provide an overview of how Ascendis is applying its TransCon™ technology platform and its unique algorithm for product innovation to the therapeutic area of oncology –

See original here:
Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20

To Read More: Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20
categoriaGlobal News Feed commentoComments Off on Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20 | dataNovember 12th, 2020
Read All

Supernus to Present at Two November Investor Conferences

By Dr. Matthew Watson

ROCKVILLE, Md., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present an overview and update, as well as host investor meetings, at the following virtual investor conferences in November 2020.

Read the original:
Supernus to Present at Two November Investor Conferences

To Read More: Supernus to Present at Two November Investor Conferences
categoriaGlobal News Feed commentoComments Off on Supernus to Present at Two November Investor Conferences | dataNovember 12th, 2020
Read All

Innate Pharma to Participate in upcoming investor conferences

By Dr. Matthew Watson

MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.

See the original post here:
Innate Pharma to Participate in upcoming investor conferences

To Read More: Innate Pharma to Participate in upcoming investor conferences
categoriaGlobal News Feed commentoComments Off on Innate Pharma to Participate in upcoming investor conferences | dataNovember 12th, 2020
Read All

Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

By Dr. Matthew Watson

GHENT, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020.

Read more:
Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference

To Read More: Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Sequana Medical to present at Jefferies 2020 Virtual London Healthcare Conference | dataNovember 12th, 2020
Read All

Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting

By Dr. Matthew Watson

Data presented support the potential of combining oncolytic virotherapy along with PM21-NK cell adoptive therapy against lung cancer

Continued here:
Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting

To Read More: Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting
categoriaGlobal News Feed commentoComments Off on Kiadis announces new data related to its K-NK cell therapy platform presented today at the SITC Annual Meeting | dataNovember 12th, 2020
Read All

Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox Viruses

By Dr. Matthew Watson

COPENHAGEN, Denmark, November 12, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include additional indications – specifically, monkeypox and related orthopoxvirus infections and disease in adults 18 years of age and older determined to be at high risk for exposure.

Continue reading here:
Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox Viruses

To Read More: Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox Viruses
categoriaGlobal News Feed commentoComments Off on Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox Viruses | dataNovember 12th, 2020
Read All

Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

By Dr. Matthew Watson

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2020.

Read more from the original source:
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights

To Read More: Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
categoriaGlobal News Feed commentoComments Off on Equillium Reports Third Quarter 2020 Financial Results and Business Highlights | dataNovember 10th, 2020
Read All

AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing…

By Dr. Matthew Watson

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it plans to release 12-month data for Groups 1 through 4 evaluating durability of effect and continued safety and interim data of Groups 5 and 6 evaluating safety and efficacy at higher doses for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa (XLRP) on November 11, 2020. AGTC management will host a conference call and webcast with accompanying slides to review the data and provide a general update on the XLRP trial beginning at 8:00am Eastern Time on the same date.

View post:
AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing...

To Read More: AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing…
categoriaGlobal News Feed commentoComments Off on AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing… | dataNovember 10th, 2020
Read All

Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials

By Dr. Matthew Watson

FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2020 and provided an update of its ongoing pivotal Phase 3 trials for vonoprazan.

Go here to see the original:
Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials

To Read More: Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials
categoriaGlobal News Feed commentoComments Off on Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials | dataNovember 10th, 2020
Read All

Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

NEWTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2020, and provided an update on the Company’s recent corporate developments.

View post:
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

To Read More: Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update | dataNovember 10th, 2020
Read All

Histogen Reports Third Quarter 2020 Earnings and Provides Business Update

By Dr. Matthew Watson

Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20

See the original post:
Histogen Reports Third Quarter 2020 Earnings and Provides Business Update

To Read More: Histogen Reports Third Quarter 2020 Earnings and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Histogen Reports Third Quarter 2020 Earnings and Provides Business Update | dataNovember 10th, 2020
Read All

Bioasis Announces Annual General Meeting Details

By Dr. Matthew Watson

GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announces details of its forthcoming Annual General Meeting (“the Meeting”) of shareholders. The Meeting will be held at the offices of Marcum LLP, 555 Long Wharf Dr. 8th floor, New Haven, CT 06511, USA, on Thursday December 10, 2020 at 9:00 a.m. (Eastern standard time).

See original here:
Bioasis Announces Annual General Meeting Details

To Read More: Bioasis Announces Annual General Meeting Details
categoriaGlobal News Feed commentoComments Off on Bioasis Announces Annual General Meeting Details | dataNovember 10th, 2020
Read All

Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

By Dr. Matthew Watson

TEMPLE CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11, 2020. These representatives of the company will host a presentation beginning at 3:30 p.m. ET.

Read the rest here:
Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

To Read More: Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference | dataNovember 10th, 2020
Read All

10x Genomics Reports Third Quarter 2020 Financial Results

By Dr. Matthew Watson

PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.

See original here:
10x Genomics Reports Third Quarter 2020 Financial Results

To Read More: 10x Genomics Reports Third Quarter 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on 10x Genomics Reports Third Quarter 2020 Financial Results | dataNovember 10th, 2020
Read All

Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

- Initiation of Phase 1/2a Trial of CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular Degeneration Expected by Year-End 2020 -- Phase 2 Trials Using SCS Microinjector® Ongoing by Gene Therapy and Oncology Partners -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET -

More:
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update

To Read More: Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update | dataNovember 10th, 2020
Read All

Eyenovia Reports Third Quarter 2020 Financial Results

By Dr. Matthew Watson

Company to host conference call and webcast today, November 10, at 4:30pm ET Company to host conference call and webcast today, November 10, at 4:30pm ET

See the original post here:
Eyenovia Reports Third Quarter 2020 Financial Results

To Read More: Eyenovia Reports Third Quarter 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on Eyenovia Reports Third Quarter 2020 Financial Results | dataNovember 10th, 2020
Read All

Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results

By Dr. Matthew Watson

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2020.

Link:
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results

To Read More: Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results | dataNovember 10th, 2020
Read All

Page 10«..9101112..20..»